Antiretroviral Drug Repositioning for Glioblastoma
Author:
Rivas Sarah R.12, Mendez Valdez Mynor J.2, Chandar Jay S.2ORCID, Desgraves Jelisah F.2, Lu Victor M.2, Ampie Leo1, Singh Eric B.2, Seetharam Deepa2, Ramsoomair Christian K.2, Hudson Anna2, Ingle Shreya M.2, Govindarajan Vaidya2, Doucet-O’Hare Tara T.3ORCID, DeMarino Catherine1, Heiss John D.1ORCID, Nath Avindra1, Shah Ashish H.2
Affiliation:
1. Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, MD 20892, USA 2. Section of Virology and Immunotherapy, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA 3. Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Abstract
Outcomes for glioblastoma (GBM) remain poor despite standard-of-care treatments including surgical resection, radiation, and chemotherapy. Intratumoral heterogeneity contributes to treatment resistance and poor prognosis, thus demanding novel therapeutic approaches. Drug repositioning studies on antiretroviral therapy (ART) have shown promising potent antineoplastic effects in multiple cancers; however, its efficacy in GBM remains unclear. To better understand the pleiotropic anticancer effects of ART on GBM, we conducted a comprehensive drug repurposing analysis of ART in GBM to highlight its utility in translational neuro-oncology. To uncover the anticancer role of ART in GBM, we conducted a comprehensive bioinformatic and in vitro screen of antiretrovirals against glioblastoma. Using the DepMap repository and reversal of gene expression score, we conducted an unbiased screen of 16 antiretrovirals in 40 glioma cell lines to identify promising candidates for GBM drug repositioning. We utilized patient-derived neurospheres and glioma cell lines to assess neurosphere viability, proliferation, and stemness. Our in silico screen revealed that several ART drugs including reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) demonstrated marked anti-glioma activity with the capability of reversing the GBM disease signature. RTIs effectively decreased cell viability, GBM stem cell markers, and proliferation. Our study provides mechanistic and functional insight into the utility of ART repurposing for malignant gliomas, which supports the current literature. Given their safety profile, preclinical efficacy, and neuropenetrance, ARTs may be a promising adjuvant treatment for GBM.
Funder
NIH NINDS NIH NCI K12 Calabresi Award UM American Cancer Society Intramural Funding Florida Center for Brain Tumor Research NREF Dwoskin Family Fund Vivex Foundational Grant
Reference50 articles.
1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N. Engl. J. Med.,2005 2. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma;DeCordova;Front. Immunol.,2020 3. Alomari, S., Zhang, I., Hernandez, A., Kraft, C.Y., Raj, D., Kedda, J., and Tyler, B. (2021). Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature. Biomolecules, 11. 4. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine;Scanlon;Cancer Commun.,1989 5. Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: Prospective cohort study. Swiss HIV Cohort Study;Ledergerber;BMJ,1999
|
|